Drug intelligence / Profile preview

ALG-000286

Development stage: Preclinical
Lead developer: Aligos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ALG-000286 is an investigational **small molecule** hepatitis B virus capsid assembly modulator developed by Aligos Therapeutics for chronic hepatitis B infection. It is described as a **prodrug of ALG-000111**, an HBV capsid inhibitor, and belongs to the **class II CAM** category. Its antiviral mechanism is to target the **HBV capsid**, disrupting viral nucleocapsid assembly and related steps in the HBV replication cycle. Preclinical studies, including an AAV-HBV mouse model, reported potent antiviral activity with declines in HBV DNA, supporting its development as a direct-acting anti-HBV therapy.

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on ALG-000286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-000286.

Explore the full profile